Quote:

---

(2) If Leronlimab helps the standard of care and raises the PD-L1 but the treatment fails, can they continue with Leronlimab and add a checkpoint inhibitor like Keytruda (which is approved for colon and rectal cancer treatment) as a second or follow-on treatment?

---

I'm curious of this as well, but confident the company has thought of this and has a plan for a follow-on treatment or possibly even the treating oncologist has the flexibility to add an ICI if the PD-L1 biomarkers reach the medium or high levels where ICIs are more effective. As Respert noted, MSS CRC is typically not treated with an ICI due to the low effectiveness....given the TNBC results and how the company delayed the CRC trial to incorporate PD-L1 measurements into this trial further affirms my confidence.